ACADIA Pharmaceuticals Inc Q4 2020 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Gregory James Renza - RBC Capital Markets, Research Division - Analyst : Congrats on the progress. I just wanted to follow-up a bit on trofinetide, Steve. And just perhaps from -- taking a step back and just from a higher level, just wondering if you could just characterize how perhaps important you see the LAVENDER readout as it perhaps reads through to your efforts and thesis around finding those next waves of breakthroughs and your external business development model, using that as essentially the initial case study for growth beyond pimavanserin, how it suggests, and how you're looking at assets going forward and beyond to build the pipeline?

Question: Sumant Satchidanand Kulkarni - Canaccord Genuity Corp., Research Division - Analyst : Thanks again for all the detail you provided on the gross to net and potential payer dynamics. But could you talk about your philosophy on the actual magnitude and frequency of price increases of NUPLAZID? And whether that might have changed in any way, given that DRP approval is around the corner and that indication is much larger relative to PDP?